Literature DB >> 29214883

Longitudinal structural changes in ALS: a three time-point imaging study of white and gray matter degeneration.

Peter Bede1,2, Orla Hardiman1,2.   

Abstract

BACKGROUND: Cross-sectional imaging studies offer valuable pathological insights into the neurodegenerative changes of amyotrophic lateral sclerosis. However, clinical trials urgently require sensitive monitoring markers that can detect subtle progressive changes over relatively short periods of time. We have conducted a three time-point longitudinal study to explore anatomical patterns of disease spread and to determine whether MRI metrics capture longitudinal changes over four and eight-month intervals.
METHODS: Thirty-two ALS patients were enrolled into a multiparametric imaging study to evaluate progressive cortical thickness, grey matter density and white matter alterations. Whole-brain and region-of-interest analyses were conducted in the precentral gyrus, corticospinal tracts, corpus callosum and cerebellum. Additionally, pre-symptomatic changes were explored in patients with no bulbar or lower limb disability.
RESULTS: Our findings suggest that considerable white matter degeneration can be detected early in the course of the disease which shows limited progression over time, whereas grey matter pathology is relatively limited at baseline and exhibits relentless progression. Moreover, progressive presymptomatic structural changes can be identified in the bulbar and lower limb representations of the precentral gyrus.
CONCLUSIONS: Our longitudinal imaging study confirms that MRI metrics readily capture progressive changes in ALS. Our data also indicate that white matter metrics are of potential use as diagnostic markers, and grey matter measures may be superior as monitoring biomarkers. One of the most interesting findings of our study is the gradually progressive cerebellar grey matter degeneration throughout the three time-points.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; longitudinal study; motor neuron disease; multimodal imaging; presymptomatic change

Mesh:

Year:  2017        PMID: 29214883     DOI: 10.1080/21678421.2017.1407795

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  35 in total

Review 1.  The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.

Authors:  Stacey Li Hi Shing; Mary Clare McKenna; We Fong Siah; Rangariroyashe H Chipika; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-05       Impact factor: 3.978

Review 2.  Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.

Authors:  Suvi Häkkinen; Stephanie A Chu; Suzee E Lee
Journal:  Neurobiol Dis       Date:  2020-09-02       Impact factor: 5.996

3.  Extrapyramidal deficits in ALS: a combined biomechanical and neuroimaging study.

Authors:  Maryse Feron; Annabelle Couillandre; Eya Mseddi; Nicolas Termoz; Malek Abidi; Eric Bardinet; Daniel Delgadillo; Timothée Lenglet; Giorgia Querin; Marie-Laure Welter; Nadine Le Forestier; François Salachas; Gaelle Bruneteau; Maria Del Mar Amador; Rabab Debs; Lucette Lacomblez; Vincent Meininger; Mélanie Pélégrini-Issac; Peter Bede; Pierre-François Pradat; Giovanni de Marco
Journal:  J Neurol       Date:  2018-07-11       Impact factor: 4.849

4.  Regional prefrontal cortical atrophy predicts specific cognitive-behavioral symptoms in ALS-FTD.

Authors:  Elena Ratti; Kimiko Domoto-Reilly; Christina Caso; Alyssa Murphy; Michael Brickhouse; Daisy Hochberg; Nikos Makris; Merit E Cudkowicz; Bradford C Dickerson
Journal:  Brain Imaging Behav       Date:  2021-02-15       Impact factor: 3.224

Review 5.  Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

Review 6.  Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis.

Authors:  Stephen A Goutman; Orla Hardiman; Ammar Al-Chalabi; Adriano Chió; Masha G Savelieff; Matthew C Kiernan; Eva L Feldman
Journal:  Lancet Neurol       Date:  2022-03-22       Impact factor: 59.935

7.  Structural MRI outcomes and predictors of disease progression in amyotrophic lateral sclerosis.

Authors:  Edoardo G Spinelli; Nilo Riva; Paola M V Rancoita; Paride Schito; Alberto Doretti; Barbara Poletti; Clelia Di Serio; Vincenzo Silani; Massimo Filippi; Federica Agosta
Journal:  Neuroimage Clin       Date:  2020-06-17       Impact factor: 4.881

8.  Cortical progression patterns in individual ALS patients across multiple timepoints: a mosaic-based approach for clinical use.

Authors:  Marlene Tahedl; Rangariroyashe H Chipika; Jasmin Lope; Stacey Li Hi Shing; Orla Hardiman; Peter Bede
Journal:  J Neurol       Date:  2021-01-05       Impact factor: 4.849

Review 9.  Upper Motor Neuron Disorders: Primary Lateral Sclerosis, Upper Motor Neuron Dominant Amyotrophic Lateral Sclerosis, and Hereditary Spastic Paraplegia.

Authors:  Timothy Fullam; Jeffrey Statland
Journal:  Brain Sci       Date:  2021-05-11

10.  Longitudinal Study of Cognitive and Emotional Alterations in Amyotrophic Lateral Sclerosis: Clinical and Imaging Data.

Authors:  Soumia Benbrika; Franck Doidy; Laurence Carluer; Audrey Mondou; Alice Pélerin; Francis Eustache; Fausto Viader; Béatrice Desgranges
Journal:  Front Neurol       Date:  2021-07-08       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.